Newsquawk Logo

Gilead Sciences (GILD) Q1 2026 (USD): Adj. EPS 2.03 (exp. 1.91), Revenue 6.96bln (exp. 6.91bln), guides FY26 Adj. EPS between -1.05 to -0.65 and product sales between 30-30.4bln (exp. 30bln), outlook reduced due to USD 11.5bln of charges

Gilead Sciences reported a Q1 beat on both adjusted EPS and revenue, indicating better-than-expected momentum in the current quarter.

Newsquawk StaffPublished On the live feed at — 12 more headlines followed before this page went public
Newsquawk headlinesUTC

Iran and the US are discussing a one-page plan for both sides to reopen the Strait of Hormuz and end hostilities for 30 days while they try to reach a comprehensive deal, NYT reports

Air defences shot down two hostile drones over Bandar Abbas and Qeshm, Mehr News reports

Gilead Sciences (GILD) Q1 2026 (USD): Adj. EPS 2.03 (exp. 1.91), Revenue 6.96bln (exp. 6.91bln), guides FY26 Adj. EPS between -1.05 to -0.65 and product sales between 30-30.4bln (exp. 30bln), outlook reduced due to USD 11.5bln of charges

Explosions heard in Qeshm due to the confrontation of defences with small birds, ISNA reports

So far, no explosions or clashes have been reported in Sirik, and the city is completely safe, Nour News reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

However, the company's guidance for FY26 shows a significant downturn, reflecting substantial charges, which may lead to market concerns about its future profitability and stability. This mixed outcome suggests potential volatility in GILD's stock and could also impact investor sentiment broadly in the biotech sector.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.